Showing Latest Articles
Feasibility Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 for Advanced Gastric Cancer
Anticancer Research, 09/07/2011
Clinical Article
Fujitani K et al. – Triplet combination chemotherapy with paclitaxel, cisplatin and S–1 demonstrated superior feasibility and promising antitumor activity for advanced gastric cancer.
Methods- Feasibility study of a triplet combination using paclitaxel, cisplatin and S–1 for advanced gastric cancer was conducted.
- Patients were given paclitaxel 160 mg/m2 infused over 2 hours on day 1, followed by cisplatin 60 mg/m2 in a 2–hour infusion on day 14, and S–1 80 mg/m2/day for 14 consecutive days, followed by a 2–week rest, repeated every 4 weeks.
- Treatment was continued until disease progression or unacceptable toxicity occurred, the patient refused the therapy, or a surgical procedure was performed.
- 21 patients were prospectively enrolled.
- Total of 53 courses were administered, with a median of 2 courses (range: 1–7).
- Leucopenia, neutropenia, and anemia of grade 3 or more occurred in 3, 12, and 3 patients, respectively.
- Non–hematological toxicities were all grade 2 or less. Planned treatment was delivered with relative dose intensity for paclitaxel, cisplatin, and S–1 as 91.1%, 81.1% and 90.6%, respectively.
- verall response rate was 67% with 1 complete response, 13 partial responses, and 6 with stable disease, while 6 out of 13 surgically resected specimens showed a histologic response graded ≥1b.
- Median survivals of all patients and of 13 patients who underwent curative resection were 543 and 871 days, respectively.
